• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Turn Therapeutics Inc. - Common Stock (NQ:TTRX)

    3.540 -0.050 (-1.39%)
    Streaming Delayed Price Updated: 2:22 PM EST, Feb 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Turn Therapeutics Inc. - Common Stock

    News headline image
    Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
    From Turn Therapeutics Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
    From Turn Therapeutics, Inc.
    Via Business Wire
    News headline image
    Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
    Mr. Dewhurst Brings Over 30 Years of Life Sciences and M&A Experience to the Board, Aligning with the Company’s Strategic Long-Term Goals for Growth and Expansion 
    From Turn Therapeutics
    Via GlobeNewswire
    Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today? ↗
    Via Stocktwits
    News headline image
    Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
    Conversation Centered Around Healthcare Communications and Pandemic Preparedness 
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
    Turn’s Topical IL36/IL31 Inhibitor Named Alongside Other Phase 2 & 3 Candidates from Amgen, Sanofi, Leo Pharma, Apogee Therapeutics, and Nektar Therapeutics 
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
    Agreement combines Turn’s PermaFusion® delivery platform with Medline’s global scale and distribution capabilities to advance professional and retail product opportunities 
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic Milestones
    Company to host shareholder webinar today, October 22, 2025, at 2:00 PM ET to review execution milestones, pipeline progress, and capital strategy 
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
    Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research 
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Turn Therapeutics Appoints Arthur Golden to Board of Directors
    Veteran corporate advisor to strengthen governance, oversight, and strategic execution as the Company advances late-stage programs 
    From Turn Therapeutics
    Via GlobeNewswire
    News headline image
    Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings ↗
     
    Via Benzinga
    Topics Stocks
    News headline image
    US Stocks Mixed; Nasdaq Falls Over 50 Points ↗
     
    Via Benzinga
    News headline image
    Stock Market Today: S&P 500, Nasdaq Futures Tumble As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta Air Lines, Levi Strauss In Focus ↗
    U.S. stock futures fell on Thursday following Wednesday’s mixed close. Futures of major benchmark indices were lower. 
    Via Benzinga
    Topics Economy Stocks
    News headline image
    Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
     
    Via Benzinga
    News headline image
    PepsiCo, Delta Air Lines And 3 Stocks To Watch Heading Into Thursday ↗
    Stock futures mixed, investor focus on PepsiCo, Costco, and Delta earnings. Turn Therapeutics surges, while Levi Strauss reports after bell. 
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.